Mar 26, 2025 7:30am EDT Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
Mar 13, 2025 CEO Dr. Adam Mendelsohn and CBO Don Dwyer participated in a Vivani-hosted investor conference call to discuss recent progress in the LIBERATE-1 clinical trial
Sep 25, 2024 CEO Dr. Adam Mendelsohn presented at the Emerging Growth Conference on September 25, 2024.
Sep 24, 2024 CEO Dr. Adam Mendelsohn joined Daniel Levine on the September 24, 2024 installment of The Bio Report podcast to discuss Vivani Medical’s implantable drug delivery technology, how it works, and why its lead indication is a GLP-1 implant for weight loss and diabetes.